Advertisement
U.S. markets open in 1 hour 41 minutes

Endonovo Therapeutics, Inc. (ENDV)

Other OTC - Other OTC Delayed Price. Currency in USD
0.0023-0.0012 (-34.29%)
At close: 03:53PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.0035
Open0.0023
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.0022 - 0.0037
52 Week Range0.0010 - 0.0200
Volume1,697,909
Avg. Volume367,800
Market Cap733,129
Beta (5Y Monthly)-0.40
PE Ratio (TTM)N/A
EPS (TTM)-0.0700
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A

Subscribe to Yahoo Finance Plus to view Fair Value for ENDV

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • ENDONOVO THERAPEUTICS INC
    Mid Cap U.S. Pick List March 2024This pick list highlights constituents of the Morningstar US Mid Cap Index that we believe offer investors the best risk-adjusted return prospects. The market capitalization range for U.S. mid-caps typically falls between $1 billion and $8 billion and represents 20% of the total capitalization of the U.S. equity market.
    Rating
    Fair Value
    Economic Moat
    12 days agoMorningstar
View more
  • GlobeNewswire

    Endonovo’s SofPulse® to Be Featured at Innovative Pain Management Solutions

    US Army Medical Research and Development Command Vendor Day Los Angeles, CA, March 04, 2024 (GLOBE NEWSWIRE) -- SofPulse Inc. -- a subsidiary of Endonovo (OTC PINK: ENDV) and a proposed spin-off company -- announced today the participation of its SofPulse® Pulsed Electro-Magnetic Field (PEMF) FDA-cleared medical device in the United States Army Medical Research and Development Command (USAMRDC) May 2024 Vendor Day. The USAMRDC is the Army's medical materiel developer, responsible for medical res

  • GlobeNewswire

    Endonovo Signs Definitive Agreement to Sell SofPulse® Brand Business and IP to SofPulse Inc. for a minimum of $50 Million

    Los Angeles, CA, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV), a commercial-stage developer of wearable products for pain relief, general wellness, and wound curatives marketed under the SofPulse® brand name, announced the signing of a definitive agreement for the sale of the SofPulse® business and medical Intellectual Property (IP) to SofPulse, Inc.. ENDV is expected to receive the greater of $50 million or a price to be determined by a qualified third party's ass

  • GlobeNewswire

    Endonovo's SofPulse® Secures Taiwan FDA Approval

    Los Angeles, CA, Oct. 12, 2023 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) US-based medical device company, today announced the full regulatory approval of its flagship product, SofPulse® by the Taiwan Food and Drug Administration (TFDA), the regulatory division of the Ministry of Health and Welfare (MOHW). The approval is a significant accomplishment in introducing innovative Pulsed Electro Magnetic Field (PEMF) technology into the Taiwanese surgical market through Endonovo's